Surgical Science Sweden Past Earnings Performance
Past criteria checks 2/6
Surgical Science Sweden has been growing earnings at an average annual rate of 49.9%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 43.4% per year. Surgical Science Sweden's return on equity is 4.3%, and it has net margins of 22.5%.
Key information
49.9%
Earnings growth rate
45.4%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 43.4% |
| Return on equity | 4.3% |
| Net Margin | 22.5% |
| Next Earnings Update | 19 Feb 2025 |
Recent past performance updates
Recent updates
The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Revenue & Expenses Breakdown
How Surgical Science Sweden makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 860 | 193 | 242 | 191 |
| 30 Jun 24 | 838 | 198 | 239 | 181 |
| 31 Mar 24 | 842 | 208 | 233 | 181 |
| 31 Dec 23 | 883 | 234 | 240 | 182 |
| 30 Sep 23 | 906 | 253 | 236 | 182 |
| 30 Jun 23 | 901 | 234 | 228 | 185 |
| 31 Mar 23 | 872 | 221 | 221 | 179 |
| 31 Dec 22 | 803 | 188 | 202 | 173 |
| 30 Sep 22 | 750 | 138 | 200 | 159 |
| 30 Jun 22 | 640 | 124 | 176 | 130 |
| 31 Mar 22 | 489 | 101 | 146 | 97 |
| 31 Dec 21 | 367 | 86 | 117 | 66 |
| 30 Sep 21 | 209 | 30 | 76 | 37 |
| 30 Jun 21 | 138 | 21 | 60 | 26 |
| 31 Mar 21 | 122 | 18 | 53 | 20 |
| 31 Dec 20 | 105 | 16 | 50 | 17 |
| 30 Sep 20 | 104 | 14 | 51 | 18 |
| 30 Jun 20 | 112 | 19 | 54 | 19 |
| 31 Mar 20 | 107 | 17 | 52 | 19 |
| 31 Dec 19 | 102 | 13 | 51 | 17 |
| 30 Sep 19 | 88 | 6 | 49 | 15 |
| 30 Jun 19 | 70 | -5 | 43 | 13 |
| 31 Mar 19 | 68 | -5 | 43 | 13 |
| 31 Dec 18 | 66 | -5 | 39 | 14 |
| 30 Sep 18 | 60 | -3 | 38 | 10 |
| 30 Jun 18 | 57 | -6 | 37 | 7 |
| 31 Mar 18 | 56 | -7 | 34 | 4 |
| 31 Dec 17 | 57 | -3 | 31 | 0 |
| 30 Sep 17 | 65 | 4 | 30 | 0 |
| 30 Jun 17 | 60 | 3 | 27 | 0 |
| 31 Mar 17 | 59 | 4 | 27 | 0 |
| 31 Dec 16 | 58 | 3 | 29 | 0 |
| 31 Dec 15 | 52 | 2 | 24 | 0 |
| 31 Dec 14 | 41 | -3 | 21 | 0 |
Quality Earnings: SUS has high quality earnings.
Growing Profit Margin: SUS's current net profit margins (22.5%) are lower than last year (27.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SUS's earnings have grown significantly by 49.9% per year over the past 5 years.
Accelerating Growth: SUS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SUS had negative earnings growth (-23.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (31%).
Return on Equity
High ROE: SUS's Return on Equity (4.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:00 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Surgical Science Sweden AB (publ) is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Jonsson | Berenberg |
| Viktor Högberg | Danske Bank |
| Jonatan Andersson | DNB Markets |